Numerous clinical studies have been conducted to analyse the ability of renin−angiotensin system blockade to lower blood pressure and to reduce end-organ damage. In addition to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, direct renin inhibitors emerged as an attractive option to inhibit the renin−angiotensin system and thus to prevent cardiovascular damage. Based on the publication of the most recent available results of ALTITUDE and ASTRONAUT, we review the data with respect to the direct renin inhibitor aliskiren given as an antihypertensive drug, in monotherapy and combination therapy, and the most recent publication analysing the effects of aliskiren on end-organ protection.
Aliskiren is the most recent novelty on the market of antihypertensive agents that acts by inhibition of the renin−angiotensin−aldosterone-system. It intervenes at the start of the angiotensin II biosynthesis by binding directly to the protease renin, thereby inhibiting the cleavage of angiotensin I from angiotensinogen. This results, in contrast to ACE inhibition, in a complete inhibition of the renin−angiotensin system (RAS), whereby the levels of angiotensin II decline. The fact that renin is the first and rate-limiting enzymatic step in the RAS cascade and has remarkably high specificity for only one substrate, angiotensinogen, the development and introduction of aliskiren in 2007 was expected to be a great step forward in controlling blood pressure. In contrast to renin, ACE has many peptide substrates, including bradykinin. Thus, a lower rate of side effects was expected with direct renin inhibition.
Also, by direct inhibition of the enzyme renin, the physiological increase of renin concentration is prevented. This increase occurs as counter-regulation to RAS inhibition by ACE inhibitors and angiotensin receptor blockers (ARBs), and may reduce the decrease in blood pressure.
Furthermore there was the question of whether additional benefits seen in the experimental setting can be verified in humans, i.e. effects beyond blood pressure lowering, such as end-organ protection. Experiments in rats revealed that aliskiren administration reduced proteinuria, reversed cardiac hypertrophy and reduced macrophage infiltration in the heart and kidney significantly. These experimental results point to organ-protective effects with aliskiren. 1
Blood pressure-lowering effects of aliskiren
Several clinical studies analysed the ability of aliskiren, administered once a day, to reduce blood pressure in comparison to ramipril, 2 losartan, 3 irbesartan 4 and hydrochlorothiazide. 5 In these studies in patients with mild-to-moderate essential hypertension, aliskiren led to a decrease of blood pressure similar to or even stronger than the effect induced by the active comparator, with a safety profile similar to those of the ARBs. As a consequence of these and further studies, aliskiren was approved as an antihypertensive agent by the Federal Drug Administration (FDA) in the USA and by the European Medicines Agency (EMEA) in Europe.
Likewise the combined therapy of aliskiren with hydrochlorothiazide, amlodipine and valsartan showed an additive blood pressure-lowering effect. In a double-blind, randomised controlled study combined RAS inhibition with aliskiren and valsartan reduced blood pressure further than monotherapy with either aliskiren or valsartan. 6 This was also confirmed by evaluating 24-hour blood pressure profiles.
Combined RAS inhibition and endorgan protection
Next, the question was addressed of whether dual or sequential RAS blockade with aliskiren if combined with ACE inhibitors or ARBs have synergistic and additional protective effects on hypertension-associated end-organ damage. The effectiveness of RAS blockade when using an ACE inhibitor or an ARB alone has been called into question, because of the failure of ACE inhibition to block other angiotensin I−II converting enzymes (e.g. chymase) or the lack of a complete blockade of the RAS by ARBs. In the ONTARGET trial dual RAS blockade with an ACE inhibitor and ARB was not found to be superior with respect to reduction of hard cardiovascular endpoints compared with monotherapy with these drugs alone, 7 although other intermediate endpoint trials found that ACE inhibitors combined with ARBs induced a further reduction of proteinuria in patients with chronic kidney disease. 8 The ONTARGET trial involved patients with or without diabetes and endorgan damage. Of note, dual RAS blockade in this trial was related to significantly more adverse events, in particular acute renal failure, hyperkalaemia and symptomatic hypotension. 7 Similar findings have been observed with other ACE inhibitor and ARB combinations studied in patients with chronic heart failure 9−11 and postmyocardial infarction. 12 In this context the hypothesis was raised that the combination of aliskiren with an ARB is a different and superior approach since the feedback mechanism is set apart and the circulating levels of angiotensin I and angiotensin II will remain reduced. This hypothesis has been supported by clinical trials focusing on intermediate endpoints.
The AVOID trial 13 showed a reduction of albuminuria by approximately 50% in patients with hypertension, type 2 diabetes and proteinuria who were receiving a combination therapy of losartan and aliskiren twice as often as in the reference group (losartan + placebo), both on top of the concomitant antihypertensive agents and independent of the blood pressure-lowering effects. In the ALLAY trial, in which overweight patients with hypertension and LV hypertrophy received either monotherapy with aliskiren or losartan or a combination of both, it was shown that aliskiren was as effective as losartan in reducing left ventricular mass, an important sign of end-organ protection. 14 Furthermore, in the ALLAY trial, there was no clear difference in the adverse event rates (hyperkalaemia, hypotension and renal dysfunction) in the combination treatment group as opposed to the two treatment arms with monotherapy (single RAS blockade).
The potential benefit of direct renin inhibition in patients with heart failure could also be observed in the randomised, controlled ALOFT trial. 15 Here patients with chronic heart failure receiving a therapy with ACE inhibitors, β-blockers and diuretics (in one third also aldosternoe antagonists) additionally received either aliskiren or placebo. There were significantly reduced brain natriuretic peptide (BNP) concentrations in the group receiving aliskiren on top of ACE inhibition, without an increased rise of adverse events.
Hard endpoint trials
The ALTITUDE trial 16 was one of the first trials analysing the combination of an ACE inhibitor or ARB with aliskiren 300 mg once daily as opposed to monotherapy (ACE inhibitor or ARB with placebo). Over 8.000 patients with type 2 diabetes at high risk of developing cardiovascular and renal complications (albuminuria > 200 mg/g creatinine, or microalbuminuria and eGFR between 30 and 60 ml/ min/1.73 m², or a history of cardiovascular disease and eGFR between 30 and 60 ml/min/1.73 m²) were followed up over 32.9 months. The incidence of the primary endpoint (cardiovascular and renal events) was similar in the combination treatment arm and in the single RAS blockade group, and the study was interrupted by the Data Safety Monitoring Board due to 'futility' of further conducting the study. 17 Even worse, more adverse events were observed in the combination treatment arm, in particular a higher rate of hyperkalaemia. Most important, in patients developing serum potassium concentration >5.0 mmol/l, the incidence of the primary composite endpoint, as well as the cardiovascular and renal composite endpoints, were significantly increased in the combination treatment arm (Figure 1 ). 18 As a consequence, the FDA and EMEA put out a clear message that aliskiren should not be used in combination with an ACE inhibitor or ARB if type 2 diabetes was diagnosed or if patients had a GFR below 60 ml/min/1.73m².
In several studies inhibition of the neurohormonal activation, typically seen in patients with chronic heart failure, has been analysed. 10, 11 Combination of an ACE with an ARB was found to have some additional clinical benefit, however at the expense of more side effects (hypotension, adverse renal effects, hyperkalaemia). The situation might be different if patients with acute heart failure symptoms are examined due to the highly activated neurohormonal counter-regulation in such patients. Hence, a potentially more complete RAS blockade might be more beneficial. Interestingly, in patients with heart failure aliskiren was able to increase renal blood flow by enhancing renal vasodilation and boost natriuresis, 19 a finding of importance in patients with acute and chronic heart failure as they usually simultaneously show some degree of renal impairment.
The recently published ASTRONAUT trial 20 reported post-discharge mortality and heart failure readmissions among patients with acute heart failure and reduced LVEF treated with aliskiren or placebo on top of standard therapy. After 6 months there was no significant reduction of cardiovascular death or re-hospitalisation in the patients treated with aliskiren. There was a significant decrease in NT-proBNP, consistent with the findings in the ALOFT study. 15 However, patients taking aliskiren had a significantly higher rate of hyperkalaemia, worsening of renal function and hypotension episodes.
The ATMOSPHERE trial is currently being performed in patients with chronic heart failure. 21 Monotherapy with aliskiren or enalapril is compared with the combination of both. The primary endpoint is a composite cardiovascular endpoint of cardiovascular death or hospitalisation for heart failure. The hypothesis is, that in this situation of neuroendocrine activation in chronic heart failure (comparable to the one observed in CHARM 10 and VALHEFT 11 ), more complete blockade of the RAS system by aliskiren on top of an ACE inhibitor is superior to either monotherapy. We have to await the final results to judge whether in this situation the combination therapy of aliskiren with ACE inhibitors would be beneficial, also taking into consideration the potential side effects.
Conclusions: What is left?
Aliskiren is an effective and safe antihypertensive agent in monotherapy, with a placebo-like side effect profile. Dual RAS blockade (combination of aliskiren with an ACE inhibitor or ARB) has no further benefit in preventing end-organ damage in patients with type 2 diabetes at high risk of developing cardiovascular and renal complications. Whether there is any benefit of dual RAS blockade in patients with chronic heart failure is currently being investigated.
